{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall survival is the time from initiation of therapy to death from any cause.","groups":[{"description":"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.\n\nPatients were treated to a maximum response plus two additional cycles or a maximum of eight cycles.","id":"OG000","title":"Romidepsin + Bortezomib"}],"populationDescription":"Intent to treat population. However efficacy data was not analyzed due to the early termination of the study.","reportingStatus":"POSTED","timeFrame":"up to month 8","title":"Kaplan Meier Estimates for Overall Survival","type":"SECONDARY"}